Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|09/07/16||IRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology|
|Follow-up data published at European Glaucoma Society (EGS) meeting highlight six and a half years of efficacy data in patients with refractory glaucoma
MOUNTAIN VIEW, Calif., Sept. 7, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that data on its MicroPulse® P3 (MP3) device powered by the same proprietary MicroPulse laser technology in the IRIDEX Cyclo G6TM glauc... |
|08/04/16||IRIDEX Reports 2016 Second Quarter, Six-Month Results|
|Total Revenues Up 32 Percent Year-over-Year for Second Quarter;
Cyclo G6™ Glaucoma Laser System Revenues Up 66 Percent Sequentially
MOUNTAIN VIEW, Calif., Aug. 4, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 2, 2016.
Revenues were $11.9 million for the second quarter of 2016, up 32 percent from $9.0 million for the 2015 second quarter. Revenue growth was driven by the Company's Cyclo G6™ gl... |
|07/28/16||IRIDEX Announces Second Quarter 2016 Conference Call and Release Date|
|MOUNTAIN VIEW, Calif., July 28, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2016 financial results after the market closes on Thursday, August 4, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, August 4, 2016 to discuss the results of the quarter and other business developments.
Interested parties may access the live conferen... |
|07/11/16||IRIDEX Announces Atabak Mokari Will Be Chief Financial Officer And VP Corporate Development|
|MOUNTAIN VIEW, Calif., July 11, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that Atabak Mokari, 39, will join the Company as Chief Financial Officer and Vice President of Corporate Development effective July 11, 2016.
Mr. Mokari brings over 18 years of finance and strategy experience from working with leading companies in the medical technology industry. Over the course of his career, Mr. Mokari assisted his clients to reach their strategic objectives via capital ... |
|Primary IR Contact|
CFO and VP, Corporate Development
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.